1. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

immune cell

" in MedChemExpress (MCE) Product Catalog:

645

Inhibitors & Agonists

28

Screening Libraries

4

Fluorescent Dye

38

Biochemical Assay Reagents

55

Peptides

3

MCE Kits

116

Inhibitory Antibodies

96

Natural
Products

1

Recombinant Proteins

35

Isotope-Labeled Compounds

1

Antibodies

4

Click Chemistry

53

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-131166
    Curdlan
    1 Publications Verification

    Bacterial Toll-like Receptor (TLR) NO Synthase C-type Lectin-like Receptors (CTLRs) Reactive Oxygen Species (ROS) Inflammation/Immunology
    Curdlan is a polysaccharide found in bacteria, consisting of a glucose homopolymer with β-1,3-glycosidic linkages . Curdlan can be recognized by Dectin-1 (a C-type lectin receptor), inducing immune responses in tissue mast cells and enhancing dendritic cell effects in tumor immunity. Curdlan holds potential for research in cancer and immune-inflammatory diseases .
    Curdlan
  • HY-NP137

    Complement System Others
    NP-PE (Phycoerythrin) is an immune complex. The formation and transport of NP-PE (Phycoerythrin) depends on the complement system, specifically through the complement receptors CR1 and CR2. These receptors are expressed on the surface of B cells and help B cells capture and transport immune complexes. NP-PE (Phycoerythrin) can be used to study the mechanisms by which B cells capture and transport immune complexes in lymph nodes .
    NP-PE (Phycoerythrin)
  • HY-126346

    GPR84 Inflammation/Immunology
    DL-175 (compound 13) is a selective GPR84 agonist with biased agonistic activity. DL-175 can selectively activate functional responses in immune cells and induce enhanced chemotaxis and phagocytosis of human bone marrow cells. DL-175 is a potential chemical probe .
    DL-175
  • HY-153565

    Others Inflammation/Immunology
    Immune cell migration-IN-1 (compound 2) is a potent agent to inhibit immune cell migration. Immune cell migration-IN-1 can be used for research in alleviating dry eye diseases, eczema dermatitis and psoriasis .
    Immune cell migration-IN-1
  • HY-153567

    Biochemical Assay Reagents Inflammation/Immunology
    Immune cell migration-IN-2 is a potent immune cell migration inhibitor with an EC50 of 13.5 nM in a T-cell adhesion assay. Immune cell migration-IN-2 is extracted from patent WO2019001171, example 11, can be used for dry-eye and other retinal diseases research . Immune cell migration-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Immune cell migration-IN-2
  • HY-147236

    Toll-like Receptor (TLR) Inflammation/Immunology
    TLR7/8 agonist 7 (compound 10) is a TLR7/8 agonist. TLR7/8 agonist 7 activates a variety of immune cells and it can be used to synthesize immune stimulating antibody conjugate (ISAC) molecules. TLR7/8 agonist 7 can be used for the research of immunity .
    TLR7/8 agonist 7
  • HY-N10493

    Endogenous Metabolite Inflammation/Immunology
    7β,25-Dihydroxycholesterol is an endogenous metabolite and is found to act as chemoattractants for immune cells expressing EBI2 .
    7β,25-Dihydroxycholesterol
  • HY-P991257

    Interleukin Related Cancer
    MK-1966 is a humanized monoclonal antibody inhibitor targeting interleukin-10 (IL-10). MK-1966 blocks the inhibitory effects of IL-10 on immune cells such as macrophages and dendritic cells to restore anti-tumor immune responses. MK-1966 is promising for research of cancers .
    MK-1966
  • HY-143869

    MAP4K Cancer
    HPK1-IN-28 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-28 enhances the body's anti-tumor immunity. HPK1-IN-28 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 1) .
    HPK1-IN-28
  • HY-143870

    MAP4K Cancer
    HPK1-IN-29 is a potent inhibitor of HPK1. Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the activation response of dendritic cells (DCs), T cells and B cells. HPK1-IN-29 enhances the body's anti-tumor immunity. HPK1-IN-29 has the potential for the research of immune-related diseases, especially tumor (extracted from patent WO2021175270A1, compound 38) .
    HPK1-IN-29
  • HY-156996

    Others Inflammation/Immunology Cancer
    AGI-134 is a fully synthetic alpha-Gal glycolipid. AGI-134 invokes CD8+ T cell-mediated immunity. AGI-134 induces tumor cell destruction and phagocytosis .
    AGI-134
  • HY-175780

    CD28 IFNAR TNF Receptor Interleukin Related Cancer
    CD28-IN-1 (Compound 19MS-5) is a CD28 inhibitor with a KD of 12.48  μM. CD28-IN-1 has a superior binding capacity to CD28 and potently inhibits CD28-B7 interactions. CD28-IN-1 inhibits CD28-driven immune activation and suppresses cytokine (IFN-γ, IL-2 and TNF-α) production in primary human T cells co-cultured with tumor spheroids and human epithelial tissues. CD28-IN-1 can be used for tumor immunity research .
    CD28-IN-1
  • HY-12776
    GSK805
    5 Publications Verification

    ROR Inflammation/Immunology
    GSK805 is an orally active and CNS penetrant RORγt inhibitor. GSK805 inhibits RORγ and Th17 cells differentiation with pIC50 values of 8.4 and >8.2. GSK805 inhibits the function of Th17 cells. GSK805 can be used for the research of immunity .
    GSK805
  • HY-P991443

    CD73 Cancer
    IPH5301 is a human IgG1 monoclonal antibody (mAb) targeting NT5E/CD73. IPH5301 has a functionally silent Fc domain, specifically inhibits soluble and membrane CD73 enzyme activity, and restores the proliferation of immune T cells. IPH5301 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    IPH5301
  • HY-178113

    15-PGDH Others
    15-PGDH-IN-4 (Compound 40) is a 15-PGDH inhibitor with an IC50 of 1.2  nM for h15-PGDH. 15-PGDH-IN-4 can be used for immune cell function and tissue regeneration research .
    15-PGDH-IN-4
  • HY-P99199

    NI-0401

    CD3 Inflammation/Immunology
    Foralumab (NI-0401) is a potent, orally active human monoclonal antibody targeting the CD3. Foralumab modulates immune responses by human cells in NSG mice that were reconstituted with human hematopoietic stem cells .
    Foralumab
  • HY-102011
    BMS-1166
    5 Publications Verification

    PD-1/PD-L1 Inflammation/Immunology Cancer
    BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .
    BMS-1166
  • HY-P9977
    Amivantamab
    3 Publications Verification

    JNJ-61186372

    EGFR Cancer
    Amivantamab (JNJ-61186372) is a human EGFR-MET bispecific antibody with immune anticancer activity. Amivantamab inhibits ligand binding, promotes endocytosis and degradation of receptor-antibody complexes, and induces Fc-dependent cytokinesis in macrophages and antibody-dependent cytotoxicity in natural killer cells .
    Amivantamab
  • HY-108161

    Interleukin Related Others
    LF 1695 is an immunomodulator. LF 1695 enhances the proliferative response of T cells by increasing the production of IL2 (interleukin-2) or the expression of the IL2 receptor. LF 1695 also increases CONA-induced inhibitory activity in human lymphocytes. LF 1695 can be used to study the proliferative and inhibitory activity of T cell subpopulations, as well as their role in immune regulation .
    LF 1695
  • HY-155115

    Histone Demethylase PD-1/PD-L1 Cancer
    LSD1-IN-27 is an orally active LSD1 inhibitor (IC50: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer .
    LSD1-IN-27
  • HY-119339
    SX-682
    5+ Cited Publications

    CXCR Inflammation/Immunology Endocrinology Cancer
    SX-682 is an orally bioavailable, potent allosteric inhibitor of CXCR1 and CXCR2. SX-682 can block tumor myeloid-derived suppressor cells (MDSCs) recruitment and enhance T cell activation and antitumor immunity .
    SX-682
  • HY-101058

    PD-1/PD-L1 Inflammation/Immunology
    PD1-PDL1-IN 1 (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 is useful as immune modulator .
    PD1-PDL1-IN 1
  • HY-147228

    Checkpoint Kinase (Chk) Inflammation/Immunology Cancer
    NR2F6 modulator-1 is a potent nuclear receptor subfamily 2, group F, member 6 (NR2F6) modulator. NR2F6 modulator-1 can be used for researching immune modulation and modulation of cancer stem cell activity .
    NR2F6 modulator-1
  • HY-N1022

    NF-κB Inflammation/Immunology Cancer
    11-Hydroxytephrosin is a potent inhibitor of NF-kappaB. NF-kappaB is known to play a crucial role in the regulation of genes controlling the immune system, apoptosis, tumor cell growth, and tissue differentiation .
    11-Hydroxytephrosin
  • HY-P10315

    Q144-PLP(139-151)

    Transmembrane Glycoprotein Others
    [Gln144]-PLP (139-151) is an experimental antigen used to study T cells respond to both autoantigens and cross-reactive non-autoantigens. [Gln144]-PLP (139-151) activates T cells by binding to T-cell Receptor (TCR), which triggers an immune response. [Gln144]-PLP (139-151) can be used to study the regulation of autoimmune diseases .
    [Gln144]-PLP (139-151)
  • HY-P99044
    Sabatolimab
    1 Publications Verification

    MBG453

    Tim3 Inflammation/Immunology
    Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells .
    Sabatolimab
  • HY-159647

    Molecular Glues IKZF Family Cancer
    PLX-4545 is an orally active and selective cereblon-based molecular glue degrader of IKZF2 (zinc finger transcription factor Helios). PLX-4545 can reprogram immunosuppressive regulatory T cells into pro-inflammatory effector T cells, thereby enhancing anti-tumor immune responses .
    PLX-4545
  • HY-101058A

    PD-1/PD-L1 Inflammation/Immunology Cancer
    PD1-PDL1-IN 1 TFA (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 TFA is useful as immune modulator .
    PD1-PDL1-IN 1 TFA
  • HY-169017

    Toll-like Receptor (TLR) Cancer
    MTT5 is a toll-like receptor 7 (TLR7) agonist. MTT5 can couple with Deruxtecan (HY-13631E) and exert anti-tumor activity in HER2 positive solid tumors through tumor cell killing and immune activation .
    MTT5
  • HY-P4984

    Biochemical Assay Reagents Inflammation/Immunology Cancer
    Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) is a T cell proliferation activator. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) promotes the in vitro proliferation of human peripheral blood mononuclear cells (PBMC) in a dose-dependent manner. Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78) can be used in research on inflammatory and immunity, as well as cancer .
    Toxic Shock Syndrome Toxin-1 (TSST-1) (58-78)
  • HY-P10493

    Amino Acid Derivatives Cancer
    NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .
    NY-ESO-1 (157-165) peptide
  • HY-P10493A

    Amino Acid Derivatives Cancer
    NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .
    NY-ESO-1 (157-165) peptide TFA
  • HY-171019

    Biochemical Assay Reagents Others
    Lipid 119-23 is an ionizable cationic lipid which can be utilized in the formation of lipid nanoparticles and the delivery of mRNA. Lipid 119-23 exhibits an enhanced capability to express functional mCre in several categories of immune cells, spanning the liver, spleen and lung .
    Lipid 119-23
  • HY-101093
    CA-170
    2 Publications Verification

    PD-1/PD-L1 Inflammation/Immunology Cancer
    CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes .
    CA-170
  • HY-156574

    DGK Cancer
    DGKζ-IN-4 is a DGK-zeta inhibitor. DGKζ-IN-4 can be used as an active component of pharmaceutical compositions. DGKζ-IN-4 is used to treat cancers associated with immune cell activation or cancers resistant to anti-PD-1 antibody/anti-PD-11 antibody treatment .
    DGKζ-IN-4
  • HY-113512

    Influenza Virus Inflammation/Immunology
    17-HDHA is a DHA-derived specialized proresolving mediator (SPM). 17-HDHA enhances the antibody-mediated immune response against influenza virus. 17-HDHA enhances the differentiation of B cells toward the CD27 + CD38 + antibody-secreting cell phenotype, thereby strongly increasing IgM and IgG production by activated B cells .
    17-HDHA
  • HY-115885

    HDAC Inflammation/Immunology Cancer
    XP5 is a potent, orally active HDAC6 inhibitor with an IC50 of 31 nM. XP5 displays high antiproliferative activity against various cancer cell lines including the HDACi-resistant YCC3/7 gastric cancer cells (IC50=0.16-2.31 μM). XP5 enhances antitumor immunity when combined with a PD-L1 inhibitor in melanoma .
    XP5
  • HY-P991475

    Transmembrane Glycoprotein NF-κB IFNAR Cancer
    MG-1131 is a human monoclonal antibody (mAb) targeting TIGIT. MG-1131 activates NF-κB signaling in T cells and enhances NK-mediated tumor killing activity in a PVR-dependent manner. MG-1131 blocks TIGIT to increase IFN-γ secretion. MG-1131 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    MG-1131
  • HY-150187

    GPR55 ERK Calcium Channel Inflammation/Immunology
    20:4 Lyso PI is a selective G protein-coupled receptor GPR55 agonist. 20:4 Lyso PI triggers cell rounding in GPR55-expressing HEK293 cells, with an EC50 value of 10 nM. 20:4 Lyso PI promotes RhoA activation and subsequent ROCK-dependent cytoskeletal rearrangement. 20:4 Lyso PI activates the ERK signaling pathway and elevates intracellular free calcium. 20:4 Lyso PI can be used for the study of immune diseases .
    20:4 Lyso PI
  • HY-P991364

    PYX-106; BSI-060T

    Transmembrane Glycoprotein Cancer
    Aldastotug (PYX-106; BSI-060T) is a human monoclonal antibody (mAb) targeting Siglec-15/CD33L3. Aldastotug reverses Siglec-15-mediated immunosuppression and enhances T-cell proliferation. Aldastotug induces significantly increased levels of IFNγ and TNFα in T cells. Aldastotug can be used in cancer immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Aldastotug
  • HY-149356

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-31 is a PD-1/PD-L1 inhibitor (IC50=2.2 nM). PD-1/PD-L1-IN-31 promotes secretion of the IFN-γ, and induces immune activity of peripheral blood mononuclear cells (PBMCs) to inhibits tumor cells .
    PD-1/PD-L1-IN-31
  • HY-145688

    HDAC Cancer
    HDAC-IN-33 is a potent HDAC inhibitor with IC50s of 24, 46, and 47 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-33 possesses potent antiproliferation activities against tumor cells. HDAC-IN-33 shows potent antitumor efficacy in vivo That trigger antitumor immunity .
    HDAC-IN-33
  • HY-168444

    CDK Cancer
    CDK4/6-IN-23 (Compound 42) is a potent and selective CDK4/6 inhibitor, with an IC50 of 11 nM for CDK6. CDK4/6-IN-23 can significantly activate immune cells and promote the production of IL-3. CDK4/6-IN-23 has dual myeloprotective and immunomodulatory effects in 5-FU (HY-90006) chemotherapy mice .
    CDK4/6-IN-23
  • HY-160852

    Liposome Inflammation/Immunology
    YSK 12C4 is an ionizable cationic lipid primarily used to enhance siRNA cellular delivery via multifunctional envelope-type nanodevices (MEND). YSK 12C4 promotes siRNA uptake and endosomal escape, effectively silencing genes in human immune cell lines .
    YSK 12C4
  • HY-145687

    HDAC Cancer
    HDAC-IN-32 is a potent HDAC inhibitor with IC50s of 5.2, 11, and 28 nM for HDAC1, HDAC2 and HDAC6, respectively. HDAC-IN-32 possesses potent antiproliferation activities against tumor cells. HDAC-IN-32 shows potent antitumor efficacy in vivo That trigger antitumor immunity .
    HDAC-IN-32
  • HY-P99259

    FPA 008; Anti-Human CSF1R Recombinant Antibody

    c-Fms Inflammation/Immunology Cancer
    Cabiralizumab (FPA 008) is an anti-CSF1R monoclonal antibody (MAb). Cabiralizumab enhances T cell infiltration and antitumor T cell immune responses. Cabiralizumab inhibits the activation of osteoclasts and blocks bone destruction, and can be used in the research of rheumatoid arthritis (RA). Cabiralizumab can combine with Nivolumab (HY-P9903) for lung cancer research .
    Cabiralizumab
  • HY-P99032
    Monalizumab
    4 Publications Verification

    IPH2201

    Checkpoint Kinase (Chk) IFNAR Inflammation/Immunology Cancer
    Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC) .
    Monalizumab
  • HY-170950

    P2Y Receptor NOD-like Receptor (NLR) Inflammation/Immunology
    P2Y14 antagonist 1 (compound 45) is a high selective and orally active P2Y14R antagonist with an IC50 of 0.70 nM. P2Y14R antagonist 1 demonstrates significant anti-inflammatory efficacy, effectively mitigating the pulmonary infiltration of immune cells and inflammatory response through suppressing the NLRP3 signaling pathway. P2Y14R antagonist 1 has the potential for the research of acute lung injury .
    P2Y14 antagonist 1
  • HY-111449
    BAY-218
    2 Publications Verification

    AHR antagonist 1

    Aryl Hydrocarbon Receptor Inflammation/Immunology Cancer
    BAY-218 (AHR antagonist 1) is an aryl hydrocarbon receptor (AHR) antagonist. BAY-218 has AHR inhibitory activity with an IC50 of 39.9 nM in in U87 glioblastoma cells. BAY-218 can be used for the research of cancer or conditions with dysregulated immune responses .
    BAY-218
  • HY-P99431

    Alomfilimab; SAR 445256

    CD28 Inflammation/Immunology Cancer
    KY-1044 (Alomfilimab; SAR 445256) is a fully human IgG1 antibody targeting inducible costimulatory receptor (ICOS). KY-1044 depletes ICOS high cells via antibody-dependent cellular cytotoxicity (ADCC) through the engagement of FcgRIIIa. KY-1044 act as a costimulatory molecule on cells expressing lower ICOS levels, such as CD8 + TEff cells (through FcgR-dependent clustering). KY-1044 exploit the differential expression of ICOS on T-cell subtypes to improve the intratumoral immune contexture and restore an antitumor immune response .
    KY-1044

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: